Sign in
Taking people in United StatesNo phase

Individually Targeted Neuromodulation for Contamination-based OCD

Key facts

Who runs it
Mclean Hospital
Where
Belmont, United StatesSee the site
Trial code
Status
Recruiting
People taking part
50 people, planned
Started
1 Jul 2022
Planned end
30 Jun 2024
Type of study
Interventional, 3 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • cTBS
  • iTBS
  • sham
Record updated
15 March 2024

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • male or female age 18-55 years old
  • DSM-5 diagnosis of OCD as primary presenting disorder
  • CONTAM as the predominant symptom dimension (i.e., Dimension 4 (CONTAM symptoms) is the highest score on the Dimensional Yale-Brown Obsessive Compulsive Scale (D-YBOCS); participants with more than one Dimension as highest score will still be eligible as long as Dimension 4 is one of these)
  • score of ≥ 8 on Dimension 4 of the D-YBOCS
  • taking no psychiatric medications or on a stable dose of an SSRI, clomipramine, SNRI, or second generation antipsychotic for at least 4 weeks prior to enrollment. Use of PRN benzodiazepines will be permitted as long as the dose/usage has not changed significantly leading up to enrollment. No medication changes will be permitted during the study
  • have not initiated a new course of exposure and response prevention (ERP) therapy within 4 weeks of enrollment (ongoing ERP will be permitted if initiated more than 8 weeks before enrollment)

Who cannot take part

  • positive urine drug screen (other than prescribed benzodiazepines)
  • active suicidal ideation over the week prior to screening (as indicated by answering yes to questions 1 or 2 on the C-SSRS)
  • use of psychiatric medications other than permitted above
  • substance use disorder in the last 3 months (with the exception of nicotine)
  • history of schizophrenia, bipolar disorder, autism, Tourette's syndrome (current and past history of depressive, anxiety, and eating disorders permitted as long as OCD is considered the primary disorder)
  • history of traumatic brain injury, seizure disorder, neurodegenerative disease, or other organic brain disease
  • pregnancy or lactating
  • contraindication to MRI scanning or TMS

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Obsessive-compulsive disorder

This trial is currently available in United States.

  • McLean HospitalBelmont, United StatesContact: Brian P Brennan, MDTaking people

About the trial

What the trial wants to find out

Patients with obsessive-compulsive disorder (OCD) experience a wide array of different types of obsessions and compulsions. However, current treatments for OCD employ a "one size fits all" approach and are used for all patients regardless of symptom type. In this project, the investigators propose to investigate whether a novel method of transcranial magnetic stimulation specifically reduces contamination/washing symptoms - one of the most common types of OCD.

The 3 groups in the trial

  • cTBSTreatment being tested

    continuous TBS to right MFG

  • iTBSTreatment being tested

    intermittent TBS to right MFG

  • shamSham treatment, for comparison

    sham stimulation to right MFG

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Individually Targeted Neuromodulation for Contamination-based Obsessive-compulsive Disorder
Criteria questions
Built from NCT05048251, who can take part
Record updated
15 March 2024